Alprazolam Tablets Recalled for Potential Cross-Contamination Risk
Breckenridge Pharmaceuticals is recalling Alprazolam Tablets, USP 0.25mg distributed nationwide due to a potential cross-contamination risk from manufacturing deviations.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall with no reported illnesses or injuries and no confirmed contamination—only a potential risk from manufacturing deviations. Per the rubric, theoretical hazards without reported harm score at most 3, qualifying this as High severity.
Plain-English summary
Breckenridge Pharmaceuticals, Inc. is recalling Alprazolam Tablets, USP 0.25mg in 100-count, 500-count, and 1,000-count bottles distributed nationwide. The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations at the manufacturing facility that created a potential risk of cross-contamination.
The product was manufactured by Centaur Pharmaceuticals PVT. LTD. in Pune, India. Multiple lot numbers are affected across all package sizes, with expiration dates ranging from April 2023 through October 2024.
Consumers who have this medication should contact their pharmacist or healthcare provider. Do not discontinue medication without guidance from a healthcare professional. Patients taking affected lots should work with their providers to ensure continuity of care.
The recalled product
- Product
- Alprazolam Tablets, USP, 0.25mg, CIV, packaged in: a) 100-count bottle (NDC 51991-0704-01), b) 500-count bottle and c) 1,000-count bottle, Rx only, Manufactured by Centaur Pharmaceuticals PVT. LTD., Hinjewadi, Pune, INDIA, Distributed by: Breckenridge Pharmaceuticals, Inc., Berli
- Manufacturer
- Breckenridge Pharmaceutical, Inc
- Category
- Drug
- Hazard
- cross-contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #a) 5210734
- Exp 4/30/2023
- 5211451
- Exp 8/31/2024
- 5220529
- Exp 4/30/2025
- b) 5210735
- 5210736
- 5210993
- Exp 5/31/20
- 5210994
- Exp 5/31/2023
- 5211100
- Exp 6/30/2023
- 5211452
- 5211453
- 5211454
- 5211640
- Exp 10/31/2024
- 5211641
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27